{"organizations": [], "uuid": "6d7ffedf6adbfb304fe1d2db21f62a1d4df98f25", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/idUSL5N1SN1SK", "country": "US", "domain_rank": 408, "title": "BRIEF-Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business Update", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-16T15:31:00.000+03:00", "replies_count": 0, "uuid": "6d7ffedf6adbfb304fe1d2db21f62a1d4df98f25"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/idUSL5N1SN1SK", "ord_in_thread": 0, "title": "BRIEF-Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business Update", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "aml", "sentiment": "none"}, {"name": "crc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - CELYAD SA:\n* ANNOUNCED ON TUESDAY Q1 BUSINESS AND THINK TRIAL UPDATES * GRADE 4 SERIOUS ADVERSE EVENTS OCCURRED IN TWO PATIENTS OF CYAD-01 THINK TRIAL OUT OF 20 PATIENTS INCLUDED IN INTERIM SAFETY REPORT\n* THOSE TWO PATIENTS EACH EXPERIENCED A GRADE 5 EVENT THAT WAS DEEMED UNRELATED TO ADMINISTRATION\n* CYAD-01 IS CURRENTLY BEING EVALUATED AS A STAND-ALONE INVESTIGATIONAL THERAPY IN THE THINK TRIAL WITH RELAPSED REFRACTORY AML AND CRC PATIENTS\n* CYAD-01 IS ALSO BEING EVALUATED FOR BEING ADMINISTERED AFTER LYMPHODEPLETION PRECONDITIONING - RELEVANT DEPLETHINK AML AND CRC TRIALS TO BE INITIATED IN COMING WEEKS\n* IN MAY 2018, ACHIEVED IMPORTANT MILESTONE IN ITS CYAD-01 CLINICAL STRATEGY BY DOSING FIRST METASTATIC CRC PATIENTS IN THE LINK AND SHRINK TRIALS\n* NO DRUG RELATED TOXICITY WAS OBSERVED IN THE FIRST PATIENTS OF BOTH SHRINK AND LINK TRIALS\n* ENDED Q1 WITH EUR 25.1 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS\n* CONFIRMS EXISTING CASH AND CASH EQUIVALENTS AND SHORT TERM INVESTMENTS ARE SUFFICIENT TO FUND EXPENSES UNTIL END-Q1 2019\nSource text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T15:31:00.000+03:00", "crawled": "2018-05-17T14:36:20.060+03:00", "highlightTitle": ""}